IC
ZNTL icon

Ikarian Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Ikarian Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-202,203
Closed -$9.33M – 208
2022
Q1 		$9.33M Buy
202,203
+11,063
+6% +$597K 1.23% 23
2021
Q4 		$16.1M Buy
191,140
+98,796
+107% +$7.64M 2.39% 10
2021
Q3 		$6.15M Buy
+92,344
New +$5.33M 0.43% 54

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Ikarian Capital's ZNTL Position: Q2 2022 in Review

Ikarian Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2022, closing a stake of 202,203 shares — an estimated $9.33M sold.

Ikarian Capital first reported a position in ZNTL in Q3 2021 and held it in 3 quarters. The position peaked at $16.1M in Q4 2021. 122 funds tracked by Wall St. Rank hold ZNTL as of Q2 2022.

  • Ikarian Capital reported no remaining Zentalis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 202,203 Zentalis Pharmaceuticals shares in Q2 2022, an estimated $9.33M.
  • Ikarian Capital first reported a position in Zentalis Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Ikarian Capital's Zentalis Pharmaceuticals position peaked at $16.1M in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.